Could a prostate cancer drug help fight kidney cancer?

NCT ID NCT06222593

Recruiting now Disease control Sponsor: State University of New York at Buffalo Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding bicalutamide (a prostate cancer drug) to sunitinib (a standard kidney cancer drug) can help people whose kidney cancer has stopped responding to other targeted therapies. The trial will enroll 28 adults with advanced renal cell carcinoma. Researchers will check for side effects and measure if tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bicalutamide and sunitinib
What this could lead to: If it works, this could offer a new treatment option for people with advanced kidney cancer that no longer responds to standard targeted therapy.
What could go wrong: This is an early-phase trial with only 28 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell adenocarcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, RENAL CELL

Contacts and locations

Locations

UB/ Great Lakes Cancer Care
RECRUITING

Buffalo, New York, 14203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.